Navigation Links
Non-Hormonal Therapies Aid Breast Cancer Patients
Date:12/9/2008

This applies to women with metastatic or recurrent inoperable disease, report says

TUESDAY, Dec. 9 (HealthDay News) -- Over the last 35 years, non-hormonal treatments have improved overall survival of patients with advanced breast cancer.

So say Greek researchers who conducted a review of 128 clinical trials that included more than 26,000 women with the disease.

The review showed that use of anthracycline regimens led to a 22 percent relative risk reduction in overall death, compared with older single-agent chemotherapy. Single drug taxane treatment led to a relative risk reduction of 33 percent, while a combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reduction over single-agent chemotherapy.

Most of the regimens appeared to be effective whether or not women had received a prior treatment.

"Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically indistinguishable in magnitude," the review authors wrote. "Given that subsequent lines of treatment can confer similar relative benefits as the first-line setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion."

The study was published Dec. 9 in the Journal of the National Cancer Institute.

This review is important because there has been no consensus regarding the best dosage, timing, sequence or combination of therapies for treatment of metastatic breast cancer, due to the fact that standard comparators haven't been available, Dr. Philippe Bedard and Dr. Martine Piccart-Gebhart, of the Jules Bordet Institute in Brussels, Belgium, wrote in an accompanying editorial.

The finding that many of the regimens have similar relative effectiveness in both untreated and previously treated patients means that other considerations, such as toxicity, will continue to help determine the choice of regimen for individual patients, the researchers said.

"Although this network meta-analysis is unlikely to alter routine clinical practice, it provides a solid evidence-based foundation to support the observation that the survival of women diagnosed with advanced breast cancer has improved because of more active systemic chemotherapy and targeted therapy," Bedard and Piccart-Gebhart wrote. "This should provide hope to patients, investigators, industrial sponsors, and regulatory agencies alike that well-designed clinical trials with novel systemic therapies can further alter the natural history of this devastating disease."

More information

Breastcancer.org has more about recurrent and metastatic breast cancer.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Bogus Stem Cell Therapies Sold on Internet
2. Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017
3. Non-white med students reject therapies associated with their culture
4. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
5. Stem cell therapies for heart disease -- 1 step closer
6. Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies
7. Study shows steroid therapies following transplant can be eliminated
8. Study Evaluates Laser Therapies for Hair Removal
9. New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!
10. New way to control protein activity could lead to cancer therapies
11. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... "Today, MHA and mental health advocates around ... reform legislation in more than fifty years. We applaud the bipartisan action of ... officials to improving mental health services and supports in our nation. , "For ...
(Date:12/7/2016)... ... 2016 , ... OC87 Recovery Diaries (oc87recoverydiaries.com) recounts the traumatic ... unique, personal perspective through animation. , That woman is Sheri Heller, a ... private psychotherapy practice. Sheri’s mother, Pearl, lived with schizophrenia. , By using ...
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... 07, 2016 , ... The Cliff Hart Agencies, a Michigan-based ... Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing a regional ... tumor. , Jason Bauer and his family are longtime members of the Williamston ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a ... throughout the Five Boroughs, is launching a charity drive to raise funds that will ... traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the MCL, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016 Global Cervical Dysplasia Market: ... global cervical dysplasia market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/7/2016)...  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: PTN) ... disclosed underwritten public offering of units with gross ... book-running manager, Roth Capital Partners acted as lead ... for the offering. "This financing provides ... allowing us to continue advancing bremelanotide for hypoactive ...
(Date:12/7/2016)... , Dec. 7, 2016 ... on pulmonary drugs studies the current as well ... stakeholders of this report include companies and intermediaries ... pulmonary/respiratory drugs and/or drug-device combinations as well as ... report comprises an elaborate executive summary along with ...
Breaking Medicine Technology: